n jd be the number of genes with status d in the total gene list, and N kd = ∑ J j=1 n jd V jk be the number of genes with status d in study k, where k = 1, ...K and d ∈ {0, +, −}. The collection of all X ik s is denoted by X, the collection of all V jk s is denoted by V; and the collection of all parameters involved in the model is denoted by Θ. Then given X and V, the full probability model is given by
To simplify the notations, we use Θ /θ to denote the parameter set that includes all the parameters except for θ. The following list gives the full posterior conditionals derived from the full probability model (i = 1, ..., I k , j = 1, ..., J, k = 1, ..., K, d ∈ {0, +, −}); and R code for the corresponding Gibbs sampler is provided at the URL http://qbrc.swmed.edu/software/a-powerful-bayesian-metaanalysis-method-to-integrate-multiple-gene-set-enrichment-studies/
,
Next, we relax the assumption that a common variance of error σ 2 k is shared by all genes in study k, and outline the changes in the full conditionals. That is, we replace σ 2 k by σ 2 jk s when study k has sufficient samples to produce stable estimates of the gene-wise variances. Then for such studies (say k), 1. When sampling β jk s and α jk s given V jk = 1, replace σ 2 k by σ 2 jk in (S2) and (S3).
2. The step of sampling σ 2 k should be replaced by the step of sampling σ 2 jk s. That is, (S4) should be replaced by the following:
for any gene j with V jk = 1, under independent Inverse-Gamma(w, v) priors for all σ 2 jk s.
3. All the other steps remain the same as before.
S2 Additional Tables and Figures from Simulation
Gene Type Study Para. Scenarios of Simulation I 1 2 3 4 5
UR genes
.4, 0.6, 0.8, 1.0} Table S1 : Simulation I settings of five scenarios. In the first scenario, two studies with the same effect size are considered; in the second, two studies are considered but with different effect sizes. In the third, four studies instead of two are considered and everything else is the same as the first scenario. The last two scenarios consider varying effect sizes across genes, where the fourth considers two studies with the same mean of the effect sizes while the fifth considers two studies with different means of the effect sizes.
(a) Gene expression for cases Gene ID Study 1 Study 2 1-200 
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S3 Additional Tables and Figures from Data Analysis
In our data example, patients in all data sets were classified into two groups based on their survival time. We used the pamr.surv.to.class2 function in the pamr R package (Tibshirani et al. 2002; Tibshirani et al. 2003) to determine the two groups (i.e., long and short survival groups). The function splits observations into the two groups based on the Kaplan-Meier estimates. For each observation (survival time, censoring status), it computes the probability of that observation falling into one of the two survival groups. The probability is 1 or 0 for an uncensored observation depending on the survival time. For a censored observation, the probability is between 0 and 1 based on the Kaplan Meier estimate.
The following are tables and figures for the data example.
Data Set Name Number of (Controls, Cases) GSE10245 (Kuner et al. 2009) 13, 27 GSE14814 (Zhu et al. 2010) 7, 21 GSE3141 22, 36 GSE3593 12, 31 CL (Shedden et al. 2008) 17, 65 Moff (Shedden et al. 2008) 27, 52 NCI_U133A (Shedden et al. 2008) 18, 86 NCI_Lung_U133A (Shedden et al. 2008) 44, 131 DOCK9  SNRPA1  SLC35A5  FCF1  RRM2  DDX17  H3F3A  ABCC10  AURKA  MRPL3  HNRNPK  SFTPB  HOPX  HMGB2  HSPD1  BTF3  PRC1  CYCS  DEK  CYB5A  GPR116  NFIB  CBX3  YPEL5  NKX2-1  ATP5I  NBPF15  UBE2J1  TTC37  RGL1  ATP1B1  HIGD1A  CDKN3  CBLB  NDUFAB1 NUSAP1  COL4A3  ZMYM2  NUP153  CCDC90B  IFT57  TUBA1B  CTSH  CCDC59  ATP8A1  BLVRA  KIAA0101  OLA1  C1orf116  LARP1  PLOD2  FBXO38  CYP2B6  MED13L  LSM5  DENR  DPP4  IDS  NBN  ANGEL2  HSD17B6  GNS  MTIF2  N4BP2L2  MBIP  ATP6V0A1  PSMA4  MCM4  HNRNPA2B1  SIDT2  TBCA  EZH1  DBT  DNAJC21 CLPX KIAA0240 SNRPG Figure S6 : Data example-Empirical distributions of p-values from the Fisher's combined probability tests for genes in selected pathways with low estimated posterior probability of enrichment. For each pathway/gene set, the number in the parenthesis is the estimate of the corresponding posterior enrichment probability.
We also carried out the following analysis for the data example, as suggested by one of the reviewers. First, we randomly split each data set in two with the requirement that both groups will have at least three samples. Then we ran our proposed method and the MAPEs at their default settings. After obtaining an ordered list of pathways from each method, we calculated the percent of common pathways identified in the two halves among the top 5%, 10%, 15% and 20% pathways, respectively. We repeated this procedure 10 times and report the average percent values of pathways in common in the table below. The result shows that the reproducibility of the Bayesian method appears to be better or in par with the MAPE ones. Table S6 : Data example-Comparison in percentage of common pathways identified based on random half splits. S10
